Stephen Orena

1.6k total citations · 1 hit paper
23 papers, 1.2k citations indexed

About

Stephen Orena is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Stephen Orena has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Stephen Orena's work include Malaria Research and Control (8 papers), Computational Drug Discovery Methods (5 papers) and Diabetes Treatment and Management (5 papers). Stephen Orena is often cited by papers focused on Malaria Research and Control (8 papers), Computational Drug Discovery Methods (5 papers) and Diabetes Treatment and Management (5 papers). Stephen Orena collaborates with scholars based in United States, Uganda and Switzerland. Stephen Orena's co-authors include Robert S. Garofalo, Timothy Coskran, Kevin Coleman, Kristina Rafidi, John D. McNeish, Joan Wicks, Jeffrey L. Stock, Audrey L. Hildebrandt, Shawn C. Black and Dominique Brees and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Stephen Orena

21 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ

2003 594 citations Robert S. Garofalo, Stephen Orena et al. Journal of Clinical Investigation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Orena United States	14	707	229	184	178	137	23	1.2k
Junli Zhang China	15	529 0.7×	277 1.2×	224 1.2×	116 0.7×	182 1.3×	39	1.1k
Kazushige Adachi Japan	14	567 0.8×	191 0.8×	108 0.6×	223 1.3×	81 0.6×	33	1.3k
Francesco Potì Italy	21	577 0.8×	131 0.6×	283 1.5×	170 1.0×	79 0.6×	52	1.2k
Danilo Landrock United States	22	988 1.4×	145 0.6×	188 1.0×	216 1.2×	230 1.7×	40	1.4k
Tomas Welbourne United States	19	592 0.8×	224 1.0×	113 0.6×	182 1.0×	95 0.7×	49	1.4k
В. В. Носиков Russia	22	764 1.1×	193 0.8×	156 0.8×	295 1.7×	133 1.0×	101	1.6k
Y. Inaba Japan	20	635 0.9×	237 1.0×	175 1.0×	150 0.8×	259 1.9×	37	1.4k
Masaki Igarashi Japan	18	473 0.7×	280 1.2×	229 1.2×	106 0.6×	140 1.0×	39	1.3k
Salman Azhar United States	22	687 1.0×	303 1.3×	242 1.3×	372 2.1×	170 1.2×	51	1.4k
Leena Strauss Finland	27	611 0.9×	108 0.5×	161 0.9×	433 2.4×	113 0.8×	49	1.9k

Countries citing papers authored by Stephen Orena

Since Specialization

Citations

This map shows the geographic impact of Stephen Orena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Orena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Orena more than expected).

Fields of papers citing papers by Stephen Orena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Orena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Orena. The network helps show where Stephen Orena may publish in the future.

Co-authorship network of co-authors of Stephen Orena

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Orena. A scholar is included among the top collaborators of Stephen Orena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Orena. Stephen Orena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orena, Stephen, Patrick K. Tumwebaze, Thomas Katairo, et al.. (2025). Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019–2024. Nature Communications. 16(1). 7353–7353.

Shoue, Douglas A., Lisa A. Checkley, Stephen Orena, et al.. (2024). The extended recovery ring-stage survival assay is a scalable alternative for artemisinin susceptibility phenotyping of fresh Plasmodium falciparum isolates. Antimicrobial Agents and Chemotherapy. 68(12). e0118324–e0118324. 1 indexed citations

Orena, Stephen, Patrick K. Tumwebaze, Oswald Byaruhanga, et al.. (2024). Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates. Antimicrobial Agents and Chemotherapy. 68(9). e0046624–e0046624.

Tumwebaze, Patrick K., Oswald Byaruhanga, Stephen Orena, et al.. (2022). Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors. Antimicrobial Agents and Chemotherapy. 66(10). e0081722–e0081722. 2 indexed citations

Tumwebaze, Patrick K., Melissa D. Conrad, Stephen Orena, et al.. (2022). Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda. Nature Communications. 13(1). 6353–6353. 63 indexed citations

Tumwebaze, Patrick K., Oswald Byaruhanga, Thomas Katairo, et al.. (2021). Associations between Varied Susceptibilities to PfATP4 Inhibitors and Genotypes in Ugandan Plasmodium falciparum Isolates. Antimicrobial Agents and Chemotherapy. 65(10). e0077121–e0077121. 1 indexed citations

Tumwebaze, Patrick K., Thomas Katairo, Oswald Byaruhanga, et al.. (2021). Drug susceptibility of Plasmodium falciparum in eastern Uganda: a longitudinal phenotypic and genotypic study. The Lancet Microbe. 2(9). e441–e449. 38 indexed citations

Tumwebaze, Patrick K., Oswald Byaruhanga, Thomas Katairo, et al.. (2021). Decreased Susceptibility to Dihydrofolate Reductase Inhibitors Associated With Genetic Polymorphisms in Ugandan Plasmodium falciparum Isolates. The Journal of Infectious Diseases. 225(4). 696–704. 4 indexed citations

Tsuchiya, Hiroyuki, Kerry-Ann da Costa, Barbara Renga, et al.. (2015). Interactions Between Nuclear Receptor SHP and FOXA1 Maintain Oscillatory Homocysteine Homeostasis in Mice. Gastroenterology. 148(5). 1012–1023.e14. 48 indexed citations

10.

Orena, Stephen, et al.. (2015). Extracts of Fruits and Vegetables Activate the Antioxidant Response Element in IMR-32 Cells. Journal of Nutrition. 145(9). 2006–2011. 10 indexed citations

11.

Orena, Stephen, Tristan S. Maurer, Li She, et al.. (2013). PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Frontiers in Pharmacology. 4. 115–115. 44 indexed citations

12.

Swick, Andrew G., Stephen Orena, & Annalouise O’Connor. (2013). Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism. 62(8). 1070–1073. 77 indexed citations

13.

Ammirati, Mark, Kim Andrews, Dennis E. Danley, et al.. (2009). (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: A potent, selective, orally active dipeptidyl peptidase IV inhibitor. Bioorganic & Medicinal Chemistry Letters. 19(7). 1991–1995. 33 indexed citations

14.

Greene, Michael W., Mary S. Ruhoff, Christine M. Burrington, Robert S. Garofalo, & Stephen Orena. (2009). TNFα activation of PKCδ, mediated by NFκB and ER stress, cross-talks with the insulin signaling cascade. Cellular Signalling. 22(2). 274–284. 33 indexed citations

15.

Wright, Stephen W., Mark Ammirati, Kim Andrews, et al.. (2007). (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization. Bioorganic & Medicinal Chemistry Letters. 17(20). 5638–5642. 13 indexed citations

16.

Wright, Stephen W., Mark Ammirati, Kim Andrews, et al.. (2006). cis-2,5-Dicyanopyrrolidine Inhibitors of Dipeptidyl Peptidase IV: Synthesis and in Vitro, in Vivo, and X-ray Crystallographic Characterization. Journal of Medicinal Chemistry. 49(11). 3068–3076. 28 indexed citations

17.

Garofalo, Robert S., Stephen Orena, Kristina Rafidi, et al.. (2003). Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. Journal of Clinical Investigation. 112(2). 197–208. 594 indexed citations breakdown →

18.

Orena, Stephen, et al.. (2000). Inhibition of Glycogen-synthase Kinase 3 Stimulates Glycogen Synthase and Glucose Transport by Distinct Mechanisms in 3T3-L1 Adipocytes. Journal of Biological Chemistry. 275(21). 15765–15772. 98 indexed citations

19.

Kreutter, David K., et al.. (1993). Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. American Journal of Physiology-Endocrinology and Metabolism. 264(4). E606–E613. 37 indexed citations

20.

Kreutter, David K., Stephen Orena, & Kim Andrews. (1989). Suppression of insulin-Stimulated glucose transport in L6 myocytes by calcitonin gene-related peptide. Biochemical and Biophysical Research Communications. 164(1). 461–467. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact